Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 46

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

Sayed, Shady, Sidorova, Olga A., Hennig, Alexander, Augsburg, Martina, Cortés Vesga, Catherine P., Abohawya, Moustafa, Schmitt, Lukas T., Sürün, Duran, Stange, Daniel E., Mircetic, Jovan, Buchholz, Frank · 2022 · Cancer Research

Published version of a preprint

Abstract

KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their dependence on mutant KRAS. However, analysis of the remaining cell population after long-term Cas9 expression unmasked the occurence of oncogenic KRAS escape variants that were resistant to Cas9-cleavage. In contrast, the use of an adenine base editor to correct oncogenic KRAS mutations progressively depleted the targeted cells without the appearance of escape variants and allowed efficient and simultaneous correction of a cancer-associated TP53 mutation. Oncogenic KRAS and TP53 base editing was possible in patient-derived cancer organoids, suggesting that base editor approaches to correct oncogenic mutations could be developed for functional interrogation of vulnerabilities in a personalized manner for future precision oncology applications. Significance: Repairing KRAS mutations with base editors can be used for providing a better understanding of RAS biology and may lay the foundation for improved treatments for KRAS-mutant cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-21-2519

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 41

  1. Christensen, 2020, Targeting Kras g12c-mutant cancer with a mutation-specific inhibitor, J Intern Med, 288, 183, 10.1111/joim.13057 · DOI
  2. Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
  3. Bäumer, 2015, Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer, Clin Cancer Res, 21, 1383, 10.1158/1078-0432.CCR-13-2017 · DOI
  4. Gebler, 2017, Inactivation of cancer mutations utilizing CRISPR/Cas9, J Natl Cancer Inst, 109, 1546, 10.1093/jnci/djw183 · DOI
  5. Li, 2020, Programmable base editing of mutated TERT promoter inhibits brain tumour growth, Nat Cell Biol, 22, 282, 10.1038/s41556-020-0471-6 · DOI
  6. Chen, 2013, Dynamic imaging of genomic Loci in living human cells by an optimized CRISPR/Cas system, Cell, 155, 1479, 10.1016/j.cell.2013.12.001 · DOI · Paper page
  7. Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat Protoc, 8, 2281, 10.1038/nprot.2013.143 · DOI · Paper page
  8. Zafra, 2018, Optimized base editors enable efficient editing in cells, organoids and mice, Nat Biotechnol, 36, 888, 10.1038/nbt.4194 · DOI · Paper page
  9. Sayed, 2019, CRISPR/Cas9 as a tool to dissect cancer mutations, Methods, 164–165, 36, 10.1016/j.ymeth.2019.05.007 · DOI
  10. Hennig, 2019, CFTR Expression analysis for subtyping of human pancreatic cancer organoids, Stem Cells Int, 2019, 1
  11. Seidlitz, 2019, Human gastric cancer modelling using organoids, Gut, 68, 207, 10.1136/gutjnl-2017-314549 · DOI · Paper page
  12. Kluesner, 2018, EditR: a method to quantify base editing from sanger sequencing, CRISPR J, 1, 239, 10.1089/crispr.2018.0014 · DOI · Paper page
  13. Clement, 2019, CRISPResso2 provides accurate and rapid genome editing sequence analysis, Nat Biotechnol, 37, 224, 10.1038/s41587-019-0032-3 · DOI · Paper page
  14. Li, 2018, Minimap2: pairwise alignment for nucleotide sequences, Bioinformatics, 34, 3094, 10.1093/bioinformatics/bty191 · DOI · Paper page
  15. Lawrence, 2013, Software for computing and annotating genomic ranges, PLoS Comput Biol, 9, e1003118EP, 10.1371/journal.pcbi.1003118 · DOI · Paper page
  16. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  17. Picardi, 2013, REDItools: high-throughput RNA editing detection made easy, Bioinformatics, 29, 1813, 10.1093/bioinformatics/btt287 · DOI · Paper page
  18. Rees, 2018, Base editing: precision chemistry on the genome and transcriptome of living cells, Nat Rev Genet, 19, 770, 10.1038/s41576-018-0059-1 · DOI · Paper page
  19. Pruitt, 2000, Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells, J Biol Chem, 275, 40916, 10.1074/jbc.M006682200 · DOI
  20. Agbunag, 2004, Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells, Cancer Res, 64, 5659, 10.1158/0008-5472.CAN-04-0807 · DOI
  21. Fan, 1997, K-ras modulates the cell cycle via both positive and negative regulatory pathways, Oncogene, 4, 2595, 10.1038/sj.onc.1201105 · DOI
  22. Xin, 2019, Off-Targeting of Base Editors: BE3 but not ABE induces substantial off-target single nucleotide variants, Signal Transduct Target Ther, 4, 9, 10.1038/s41392-019-0044-y · DOI
  23. Kastenhuber, 2017, Putting p53 in context, Cell, 170, 1062, 10.1016/j.cell.2017.08.028 · DOI · Paper page
  24. Hu, 2021, Targeting mutant p53 for cancer therapy: direct and indirect strategies, J Hematol Oncol, 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
  25. Steckel, 2012, Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies, Cell Res, 22, 1227, 10.1038/cr.2012.82 · DOI · Paper page
  26. Dwane, 2020, Project score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets, Nucleic Acids Res, 6, 38
  27. Kim, 2018, Targeting mutant KRASwith CRISPR-Cas9 controls tumor growth, Genome Res, 28, 374, 10.1101/gr.223891.117 · DOI · Paper page
  28. Arbab, 2020, Determinants of base editing outcomes from target library analysis and machine learning, Cell, 182, 643, 10.1016/j.cell.2020.05.037 · DOI · Paper page
  29. Chu, 2021, Rationally designed base editors for precise editing of the sickle cell disease mutation, CRISPR J, 4, 169, 10.1089/crispr.2020.0144 · DOI
  30. Tan, 2019, Engineering of high-precision base editors for site-specific single nucleotide replacement, Nat Commun, 10, 439, 10.1038/s41467-018-08034-8 · DOI · Paper page
  31. Grünewald, 2019, CRISPR DNA base editors with reduced RNA off-target and self-editing activities, Nat Biotechnol, 37, 1041, 10.1038/s41587-019-0236-6 · DOI · Paper page
  32. Kerk, 2021, Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment, Nat Rev Cancer, 21, 510, 10.1038/s41568-021-00375-9 · DOI · Paper page
  33. Pupo, 2019, KRAS-Driven metabolic rewiring reveals novel actionable targets in cancer, Front Oncol, 9, 848, 10.3389/fonc.2019.00848 · DOI
  34. Kamphorst, 2015, Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein, Cancer Res, 75, 544, 10.1158/0008-5472.CAN-14-2211 · DOI · Paper page
  35. Gradiz, 2016, MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors, Sci Rep, 6, 21648, 10.1038/srep21648 · DOI · Paper page
  36. Salgia, 2021, The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC), Cell Rep Med, 2, 100186, 10.1016/j.xcrm.2020.100186 · DOI · Paper page
  37. Ndlovu, 2018, Fibroblast growth factor 10 in pancreas development and pancreatic cancer, Front Genet, 9, 482, 10.3389/fgene.2018.00482 · DOI
  38. Levy, 2020, Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses, Nat Biomed Eng, 4, 97, 10.1038/s41551-019-0501-5 · DOI · Paper page
  39. Zeng, 2020, Therapeutic base editing of human hematopoietic stem cells, Nat Med, 26, 535, 10.1038/s41591-020-0790-y · DOI · Paper page
  40. Lim, 2022, Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases, Nat Commun, 13, 366, 10.1038/s41467-022-27962-0 · DOI
  41. Xu, 2021, Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing, Mol Cell, 81, 4333, 10.1016/j.molcel.2021.08.008 · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Cortés Vesga, C. P., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., & Buchholz, F.
Venue
Cancer Research
Published
2022-07-08
Volume
82
Issue
17
Pages
3002-3015
ISSN
  • 0008-5472
  • 1538-7445
Cited by
46
References
16
Language
en
Funders
European commission H2020 (825825)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-2519
The paper
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Cortés Vesga, C. P., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., & Buchholz, F. (2022). Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-2519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.